A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors
Details
Publication Year 2023-10-11,Volume 4,Issue #11,Page 101242
Journal Title
Cell Reports Medicine
Publication Type
Research article
Abstract
Simultaneous inhibition of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) with bispecific antibodies may improve efficacy over single-agent treatment while limiting toxicity. Cadonilimab is a humanized, bispecific antibody targeting PD-1 and CTLA-4. This is a phase 1 study of cadonilimab including dose escalation (n = 39) and dose expansion (n = 80). One dose-limiting toxicity event is observed, with the maximum tolerated dose not reached. 6 mg/kg cadonilimab once every 2 weeks is established as the recommended dose for future studies. The most common treatment-related adverse event is infusion-related reaction (18.5%), mostly grade 1/2 in severity. The incidences of any grade and grade >/=3 immune-related adverse events are 44.5% and 6.7%, respectively. The confirmed overall response rate is 13.4%, and the median duration of response is 12.9 months. Cadonilimab is well tolerated and showed promising efficacy in patients with advanced solid tumors. This study is registered with ClinicalTrials.gov: NCT03261011.
Publisher
Cell Press
Keywords
Ctla-4; Pd-1; advanced solid tumors; bispecific antibody; cadonilimab; immune checkpoint inhibitor
Department(s)
Medical Oncology
PubMed ID
37852261
Open Access at Publisher's Site
https://doi.org/10.1016/j.xcrm.2023.101242
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-11-30 06:12:30
Last Modified: 2023-11-30 06:21:19

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙